A5079470878- Pancreatic and Hepatic Oncology Research
- Cancer Immunotherapy and Biomarkers
- Lung Cancer Treatments and Mutations
- Head and Neck Cancer Studies
- Cancer Genomics and Diagnostics
- Salivary Gland Tumors Diagnosis and Treatment
- Tumors and Oncological Cases
- Ear and Head Tumors
- Thyroid Cancer Diagnosis and Treatment
- Cancer Diagnosis and Treatment
- Lung Cancer Research Studies
- Cancer and Skin Lesions
- Inflammatory Biomarkers in Disease Prognosis
- Neuroendocrine Tumor Research Advances
- MicroRNA in disease regulation
- Nonmelanoma Skin Cancer Studies
- BRCA gene mutations in cancer
- Hedgehog Signaling Pathway Studies
- Tuberculosis Research and Epidemiology
- RNA modifications and cancer
- Circular RNAs in diseases
- Radiomics and Machine Learning in Medical Imaging
- Multiple and Secondary Primary Cancers
- Melanoma and MAPK Pathways
- Renal cell carcinoma treatment
Policlinico S.Orsola-Malpighi
2018-2025
University of Bologna
2018-2025
Azienda USL di Bologna
2020-2025
Institut Curie
2024
Fondazione IRCCS Istituto Nazionale dei Tumori
2021-2023
Istituti di Ricovero e Cura a Carattere Scientifico
2021
Charles River Laboratories (Netherlands)
2021
John Wiley & Sons (United States)
2021
University of Milan
2021
Hudson Institute
2021
Although immune checkpoint inhibitors (ICIs) are associated with different immune-related adverse events (irAEs), the potential effect on skeleton is poorly defined albeit biologically plausible and assessable through pharmacovigilance. We described a case series of patients experiencing skeletal fractures while ICIs at National Cancer Institute Milan. To better characterize clinical features irAEs reported ICIs, we queried FDA Adverse Event Reporting System (FAERS) performed...
Background: Laryngeal neuroendocrine tumors (NETs) represent less than 1% of all malignancies originating from the larynx and available data are limited on case reports. Calcitonin secreting laryngeal NETs extremely rare serial dosing calcitonin in these patients might reveal early relapse or persistence. Case Description: We report a 71-year-old woman with persistent pharyngodynia who underwent surgery for an initial diagnosis small cell undifferentiated carcinoma (SCUNC) (on epiglottis...
Purpose of review To summarize the actual antibody-drug conjugates (ADCs) tested for patients with advanced head and neck squamous cell carcinoma (HNSCC), outlining results safety efficacy through published clinical trials. Recent findings ADCs combine specificity mAbs cytotoxic drug (known as payload) via a chemical linker it is designed to selectively deliver ultratoxic payload directly target cancer cells. date, various have been investigated in multiple solid malignancies others are...
Despite the genomic characterization of pancreatic cancer (PC), marked advances in development prognosis classification and novel therapeutic strategies have yet to come. The present study aimed better understand alterations associated with invasive phenotype PC, order improve patient selection for treatment options. A total 30 PC samples were analysed by either whole transcriptome (9 samples) or exome sequencing (21 on an Illumina platform (75X2 100X2 bp), results matched normal DNA...
Background: For patients with head and neck squamous cell carcinoma (HNSCC), after a single or multi-modality treatment, specific follow-up strategy is needed, but there no agreement between the main international societies on proper methods timing of follow-up. Methods: We performed descriptive review to evaluate available data compare guidelines, giving some practical guidance perform effective personalized strategies. Results Conclusions: While clinical endoscopic alone seems be...
Metastatic pancreatic cancer has a median overall survival of less than 12 months, even if treated with chemotherapy. Selected patients oligometastatic disease could benefit from multimodal treatments connecting chemotherapy and surgical treatment or radiofrequency ablation (RFA) metastases.We present patient recurrence who was successfully therapeutic approach. A 57-year-old male initially presenting resectable underwent pancreatoduodenectomy. The histopathological diagnosis revealed ductal...
Abstract Introduction In advanced basal cell carcinoma (BCC), the issue of whether Hedgehog inhibitors (HHIs) should be stopped or not after clinical complete response (cCR) achievement remains an unmet need. Materials and Methods We conducted a retrospective, multicenter study across 7 Italian dermato-oncology units including patients with BCC who continued vismodegib cCR between 2012 2019. assessed relationship duration intake (days to [DTCR], days stop [DTS], total treatment [TTD]),...